Roger Morgan

431 total citations
22 papers, 312 citations indexed

About

Roger Morgan is a scholar working on Surgery, Nutrition and Dietetics and Economics and Econometrics. According to data from OpenAlex, Roger Morgan has authored 22 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Surgery, 5 papers in Nutrition and Dietetics and 4 papers in Economics and Econometrics. Recurrent topics in Roger Morgan's work include Lipoproteins and Cardiovascular Health (10 papers), Pharmaceutical Economics and Policy (4 papers) and Clinical Nutrition and Gastroenterology (3 papers). Roger Morgan is often cited by papers focused on Lipoproteins and Cardiovascular Health (10 papers), Pharmaceutical Economics and Policy (4 papers) and Clinical Nutrition and Gastroenterology (3 papers). Roger Morgan collaborates with scholars based in United States and Japan. Roger Morgan's co-authors include Craig A. Sponseller, Stuart Campbell, Christine Yu, Michael H. Davidson, Lon S. Schneider, Hank Safferstein, Kelsie Mozzoni, Michael Grundman, Nicholas J. Izzo and Steven T. DeKosky and has published in prestigious journals such as The Journal of Immunology, Journal of the American College of Cardiology and Critical Care Medicine.

In The Last Decade

Roger Morgan

22 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roger Morgan United States 11 110 93 45 42 41 22 312
Marie-Paule Gascon Switzerland 8 51 0.5× 69 0.7× 53 1.2× 41 1.0× 18 0.4× 9 448
K‐S Yu South Korea 10 54 0.5× 94 1.0× 31 0.7× 28 0.7× 47 1.1× 14 376
Takanobu Matsuzaki Japan 13 36 0.3× 129 1.4× 25 0.6× 36 0.9× 32 0.8× 26 499
Lars-Olof Eriksson Sweden 9 252 2.3× 37 0.4× 82 1.8× 64 1.5× 19 0.5× 9 428
Megha Nagle United States 9 33 0.3× 223 2.4× 39 0.9× 66 1.6× 23 0.6× 9 742
Sweta Tandra United States 6 156 1.4× 101 1.1× 80 1.8× 44 1.0× 104 2.5× 9 616
Christian Mignat Germany 9 76 0.7× 95 1.0× 102 2.3× 53 1.3× 11 0.3× 12 404
K. Frislid Norway 14 216 2.0× 96 1.0× 40 0.9× 63 1.5× 23 0.6× 22 516
Xiaozhou Yao United States 8 116 1.1× 165 1.8× 22 0.5× 18 0.4× 57 1.4× 12 382
Andrew D. Sumner United States 10 216 2.0× 130 1.4× 60 1.3× 14 0.3× 91 2.2× 19 496

Countries citing papers authored by Roger Morgan

Since Specialization
Citations

This map shows the geographic impact of Roger Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Morgan more than expected).

Fields of papers citing papers by Roger Morgan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Morgan. The network helps show where Roger Morgan may publish in the future.

Co-authorship network of co-authors of Roger Morgan

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Morgan. A scholar is included among the top collaborators of Roger Morgan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Morgan. Roger Morgan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grundman, Michael, Roger Morgan, Jason D. Lickliter, et al.. (2018). A phase 1 clinical trial of the sigma‐2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 5(1). 20–26. 80 indexed citations
2.
Catalano, Susan M., Michael Grundman, Lon S. Schneider, et al.. (2017). [P4–567]: A PHASE 1 SAFETY TRIAL OF THE Aβ OLIGOMER RECEPTOR ANTAGONIST CT1812. Alzheimer s & Dementia. 13(7S_Part_32). 4 indexed citations
3.
Catalano, Susan M., Michael Grundman, Lon S. Schneider, et al.. (2016). P4‐381: A Two‐Part, Double‐Blind, Placebo‐Controlled, Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers. Alzheimer s & Dementia. 12(7S_Part_24). 6 indexed citations
4.
5.
Yu, Christine, Stuart Campbell, Craig A. Sponseller, et al.. (2014). Steady-State Pharmacokinetics of Darunavir/Ritonavir and Pitavastatin when Co-administered to Healthy Adult Volunteers. Clinical Drug Investigation. 34(7). 475–482. 12 indexed citations
6.
Sponseller, Craig A., et al.. (2014). After 52 Weeks, Pitavastatin Superior to Pravastatin on LDL-C Lowering in Patients with HIV†. Journal of clinical lipidology. 8(3). 333–334. 5 indexed citations
7.
Sponseller, Craig A., et al.. (2013). Pitavastatin 4 mg Provides Superior LDL-C Reduction vs. Pravastatin 40 mg Over 12 weeks in HIV-Infected Adults with Dyslipidemia, the INTREPID Trial. Journal of clinical lipidology. 7(3). 260–260. 8 indexed citations
8.
Morgan, Roger, et al.. (2012). Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult Volunteers. JAIDS Journal of Acquired Immune Deficiency Syndromes. 60(2). 158–164. 24 indexed citations
9.
10.
11.
Morgan, Roger, et al.. (2012). Pitavastatin 4 mg Is Superior to Pravastatin 40 mg in LDL-C Reduction: Results from PREVAIL US Trial in Primary Hyperlipidemia or Mixed Dyslipidemia†. Journal of clinical lipidology. 6(3). 280–282. 2 indexed citations
12.
Brass, Eric P., Leslie T. Cooper, Roger Morgan, & William R. Hiatt. (2011). A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. Journal of Vascular Surgery. 55(2). 381–389.e1. 15 indexed citations
13.
Hunt, Thomas L., et al.. (2011). Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Pitavastatin on Steady-State Warfarin in Healthy Adult Volunteers. The Journal of Clinical Pharmacology. 51(9). 1302–1309. 14 indexed citations
14.
Yu, Christine, Stuart Campbell, Baojin Zhu, et al.. (2011). Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Current Medical Research and Opinion. 28(2). 187–194. 21 indexed citations
15.
Morgan, Roger, et al.. (2010). MS390 TIME OF DAY DOSING DOES NOT INFLUENCE STEADY-STATE PHARMACOKINETICS OR LDL-C REDUCTION PRODUCED BY PITAVASTATIN. Atherosclerosis Supplements. 11(2). 188–189. 1 indexed citations
16.
Rahangdale, Shilpa, Roger Morgan, Thomas C. Ryan, et al.. (2006). Chemokine Receptor CXCR3 Desensitization by IL-16/CD4 Signaling Is Dependent on CCR5 and Intact Membrane Cholesterol. The Journal of Immunology. 176(4). 2337–2345. 17 indexed citations
17.
Scholten, Donald J., Roger Morgan, Alan T. Davis, & Roxie M. Albrecht. (1990). Failure of BCAA supplementation to promote nitrogen retention in injured patients.. Journal of the American College of Nutrition. 9(2). 101–106. 6 indexed citations
18.
Morgan, Roger, et al.. (1986). Addition of branched-chain amino acids to parenteral nutrition of stressed critically ill patients. Critical Care Medicine. 14(8). 685–688. 13 indexed citations
19.
Scholten, Donald J., Alan T. Davis, Roger Morgan, Roxie M. Albrecht, & Richard E. Dean. (1986). CARNITINE LOSSES IN THE STRESSED CRITICALLY ILL. Critical Care Medicine. 14(4). 335–335. 1 indexed citations
20.
Morgan, Roger, et al.. (1981). Maturation of Sympathetic Neurotransmission in the Rat Heart. Developmental Neuroscience. 4(1). 15–24. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie-Paule Gascon Breakdown of academic impact, for papers by K‐S Yu Breakdown of academic impact, for papers by Takanobu Matsuzaki Breakdown of academic impact, for papers by Lars-Olof Eriksson Breakdown of academic impact, for papers by Megha Nagle Breakdown of academic impact, for papers by Sweta Tandra Breakdown of academic impact, for papers by Christian Mignat Breakdown of academic impact, for papers by K. Frislid Breakdown of academic impact, for papers by Xiaozhou Yao Breakdown of academic impact, for papers by Andrew D. Sumner
Rankless by CCL
2026